Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters A Receiver Operating Characteristic Curve Modeling Approach
|
|
- Herbert Farmer
- 8 years ago
- Views:
Transcription
1 Hematopathology / Umbilical Cord Blood Selection Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters A Receiver Operating Characteristic Curve Modeling Approach José C. Jaime-Pérez, MD, PhD, Roberto Monreal-Robles, MD, Laura N. Rodríguez-Romo, MD, Consuelo Mancías-Guerra, MD, José Luís Herrera-Garza, MD, and David Gómez-Almaguer, MD Key Words: Umbilical cord blood banking; Cord blood selection; CD34+ cord blood cells; Cord blood total nucleated cell content; Cord blood volume; Receiver operating characteristic analysis; Sensitivity; Specificity DOI: /AJCPFB6EXO7BJVLR Abstract The objective of the study was to evaluate the current standard practice of using volume and total nucleated cell (TNC) count for the selection of cord blood (CB) units for cryopreservation and further transplantation. Data on 794 CB units whose CD34+ cell content was determined by flow cytometry were analyzed by using a receiver operating characteristic (ROC) curve model to validate the performance of volume and TNC count for the selection of CB units with grafting purposes. The TNC count was the best parameter to identify CB units having or more CD34+ cells, with an area under the ROC curve of (95% confidence interval, ; P <.01) and an efficiency of 75.4%. Combination of parameters (TNC/mononuclear cells [MNCs], efficiency 74.7%; TNC/volume, efficiency 68.9%; and volume/mncs, efficiency 68.3%) did not lead to improvement in CB selection. All CB units having a TNC count of or more had the required CD34+ cell dose for patients weighing 10 kg or less. Umbilical cord blood (UCB) is used as an alternative source of progenitors for hematopoietic stem cell (HSC) transplantation. Worldwide, more than 450,000 UCB units have been stored in CB banks (CBBs), and more than 10,000 UCB transplants have been performed in children and adults for a variety of disorders, 1 including hematologic malignancies, bone marrow failure syndromes, selected hereditary immunodeficiency states, and metabolic disorders. 2-5 The current status and future trends in this complex and rapidly evolving field have been recently reviewed. 6 HSCs are contained within a population of mononuclear CD34+ antigen-expressing cells, which typically represent fewer than 1% of the total leukocytes in CB. 7 The CD34+ antigen is the accepted marker for determining the HSC content in bone marrow, peripheral blood, and UCB. 8 Although no universally accepted guidelines exist, most CBBs use the combination of product weight (volume) and total nucleated cell (TNC) count as the main selection factors for cryopreservation, requiring a TNC content from 6 to for storage 9 and a minimal volume between 40 and 60 ml The CD34+ cell content has been shown to influence engraftment and survival after unrelated UCB transplantation, better predicting the hematopoietic potential of a CB unit than nucleated cell content. 13 For partially mismatched HLA transplants, the number of CD34+ cells infused is critical, with CD34+ cells per kilogram of the recipient s body weight the threshold dose. 13 Taking into account a 10% to 20% cell loss during freezing-thawing procedures, a dose of CD34+ cells per kilogram of recipient s weight before cryopreservation seems to be more suitable for the selection of CB units for storage. To know the CD34+ cell number in a CB unit could Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR 721
2 Jaime-Pérez et al / Umbilical Cord Blood Selection be relevant in several aspects, including matching the weight of the intended recipient with the appropriate unit; also, it would allow more precise selection of CB units to perform double-unit transplants for adolescents and adults, as reported. 14 However, owing to the lack of standardization of CD34+ cell counting methods, it is currently not possible to compare CD34+ cell counts among CBBs or transplant centers. Receiver operating characteristic (ROC) curve analysis is a graphic representation of the reciprocal relationship between sensitivity and specificity and provides an objective measure of the overall diagnostic performance of a test; it has been frequently used to compare diagnostic tests. 15,16 We were able to locate only 2 published reports on CB selection using ROC analysis; one focused on obstetric factors to establish selection criteria for CB cryopreservation, 17 and the other dealt with fetal biometry in which prebirth assessment of biparietal diameter might allow the selection of donors who would yield CB units of sufficient volume and cell content. 18 We decided to use formal statistical analysis and ROC curve modeling to analyze the standard practice at most CBBs for using volume and/or the TNC count for the proper selection of suitable CB units for further transplantation. Materials and Methods The characteristics of 794 CB units received between May 2005 and May 2010 at the CBB of the Hematology Department, Dr José E. Gonzalez University Hospital, School of Medicine of the Universidad Autónoma de Nuevo León, Monterrey, México, were retrospectively analyzed for this study. UCB Collection Informed consent for UCB collection was obtained from healthy women with uncomplicated pregnancies receiving care at the Obstetrics Department, University Hospital Dr. José Eleuterio González and other regional hospitals. UCB was collected by gravity into a 150-mL sterile bag collection set (Grifols, Barcelona, Spain), containing 25 ml of citratephosphate-dextrose anticoagulant. The CB unit was then stored on wet ice for transport to the CBB for processing. As do others, 10,11,19 at our CBB, we use volume and the TNC count as criteria for the selection of CB units for cryopreservation. UCB units were analyzed for nucleated cell counts and were cryopreserved if their TNC number was at least and their volume exceeded 80 ml, including the anticoagulant. The time from collection to processing was set at 48 hours or less. Laboratory Processing After removal of aliquots for routine testing, UCB in the collection bag was mixed with 6% hydroxyethyl starch (HES) in a 1:4 ratio, with 30 ml as the maximum. The buffy coat was then separated by centrifuging at 45g for 7 minutes at 10 C according to a method previously described. 20 The UCB/HES mixture and the supernatant plasma were transferred into a second plasma transfer bag without severing the connecting tube. A second centrifugation step was performed at 600g for 15 minutes at 10ºC. The cell suspension was removed into a processing set (Pall Medical, Covina, CA) and adjusted to precisely 20 ml. The equipment used to perform the volume reduction was an automated closed system, Sepax- 100 (Biosafe America, Houston, TX). The cryocyte bag was placed in the Coolmix-210 (Biosafe America), which kept it in constant agitation for adding the cryoprotective mixture, which consists of 2.5 ml of DMSO (dimethyl sulfoxide) 99.9% (Sigma-Aldrich, St Louis, MO) and 2.5 ml of Dextran 40 (Sigma-Aldrich). When the temperature reached 4ºC, the cryocyte bag was placed in a protective aluminum cassette (Medical Technology Vertriebs, Altdorf, Germany) and then deposited horizontally on a level surface inside a controlledrate freezer (Cryomed, Thermo Forma, Marietta, OH) until it reached 90 C. The units were then transferred into the liquid phase of a nitrogen freezer (Cryoplus, Thermo Forma) for long-term storage. Biologic Studies TNC Counting TNC counts were determined with an automated hematology analyzer (Sysmex XT 2000, Sysmex, Mundelein, IL) using a multiangle polarized scatter separation technique, which provides the primary TNC count. The TNC was calculated by multiplying the TNC for the total volume of the bag. The total mononuclear cell (MNC) counts were calculated by adding the absolute count of lymphocytes and monocytes reported in the CBC count and then multiplying this value for the total volume of the bag. CD34+ Cell Counting Before cryopreservation, CD34+ cell counts were determined with the ISHAGE gating strategy 21 using monoclonal antibodies anti-cd45+ fluorescein isothiocyanate (FITC; Becton Dickinson, San Jose, CA) and monoclonal antihuman CD34 class III/FITC, clone BIRMA K-3 (DAKO, Glostrup, Denmark). CD34+ cells were enumerated using a FACSCalibur flow cytometer (Becton Dickinson). Statistical Analysis Normality of the studied variables was assessed with the Kolmogorov-Smirnov test. Spearman correlation set at a significance level of.01 was performed to assess the correlation of volume and TNC and MNC counts with the CD Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR
3 Hematopathology / Original Article cell content of the CB units. ROC curve analysis was applied to evaluate the performance of volume, TNC count, and absolute MNC counts as a method for identifying CB units with a CD34+ cell content of or more, determining also the optimal operating point allowing the best performance for the CB parameter selected. We arbitrarily added different cutoff points for comparing the performance of the selected parameter at different values, determining their sensitivity, specificity, positive and negative predictive values, efficiency, and positive and negative likelihood ratios The analyzed units were divided in 2 groups depending on a CD34+ cell count, or more or fewer than as determined by flow cytometry. Descriptive statistics (percentages, mean, SD, median, and range) were used to analyze the UCB units group with a count of or more CD34+ cells, presenting the number and total CD34+ cell content of CB units that would be suitable for transplantation based on the required dose of CD34+ cells/kg, estimated for recipients weighing 10 to 40 kg. The statistical package used was SPSS, version 17.0 (SPSS, Chicago, IL). MedCalc statistical software (MedCalc, Mariakerke, Belgium) was used for ROC curve analysis. Sensitivity Specificity TNC count MNC count Volume Reference line Figure 1 Receiver operating characteristic (ROC) curve analysis comparing the performance of volume (area under the ROC curve [AUC] = 0.784), total nucleated cell (TNC) count (AUC = 0.828), and absolute mononuclear cell (MNC) count (AUC = 0.810) as criteria for selecting cord blood units suitable for cryopreservation. Results We studied 794 CB units received at our CBB during a 5-year period. By applying the current criteria, we found that our banking efficiency was 57.5%. The initial analysis revealed a direct correlation in volume, absolute TNC and MNC counts, and the total number of CD34+ cells. The TNC content had the most significant correlation with the number of CD34+ cells (r = 0.681; P <.01), compared with the MNC count (r = 0.655; P <.01) and volume (r = 0.581; P <.01). ROC analysis showed the TNC count to be the parameter with a superior area under the ROC curve, (95% confidence interval [CI], ), with a significant difference compared with the MNC count (0.810; 95% CI, ; P <.05) and volume (0.784; 95% CI, ; P <.001) Figure 1. There was no significant difference in the area under the ROC curve between volume and MNC count (P =.56). A TNC count of was the optimal operating point chosen by ROC analysis that most accurately allowed for the selection of CB units meeting the CD34+ cell content of (sensitivity, 78.7%; specificity, 70.7%) Table 1 and Figure 2. We also evaluated the performance of combining parameters (TNC/MNC, efficiency 74.7%; TNC/volume, efficiency 68.9%; and volume/mnc, efficiency 68.3%) in the function of their best cutoff values derived from the ROC curve without documenting improved performance on CB selection. Table 1 Performance Evaluation for Different ROC-Derived TNC Cutoff Values for Cord Blood Selection TNC Cutoff Value ( 10 8 ) Performance Measure * Sensitivity (%) Specificity (%) Negative predictive value (%) Positive predictive value (%) Efficiency (%) Positive likelihood ratio Negative likelihood ratio ROC, receiver operating characteristic; TNC, total nucleated cell. * Optimal operating point chosen by ROC analysis. Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR 723
4 Jaime-Pérez et al / Umbilical Cord Blood Selection Sensitivity It is interesting that when applying the ROC-selected TNC cutoff as selection criterion to the 466 CB units having a CD34+ cell content of or more, the CD34+ cell median content increased by 11%, from to , although at the expense of a 21% (n = 99) decrease in the number of CB units available for transplantation. This approach would lead to an increase in the percentage of units stored that could be safely grafted, particularly for patients weighing 15 to 25 kg Table 2 and Figure Specificity Figure 2 Receiver operating characteristic (ROC) curve analysis of absolute total nucleated cell count with an area under the ROC curve of (95% confidence interval, ; P <.01). The optimal ROC-derived cutoff (square) shown has a sensitivity of 78.7% and a specificity of 70.7%. The characteristics of the CB units meeting a CD34+ cell content of or more (n = 466 [58.7%]) were further analyzed. The median volume obtained was ml (range, ml) with a median TNC content of (range, ) and a median CD34+ cell count of (range, ) after volume reduction and before cryopreservation. Based on the requirement of CD34+ cells per kilogram of recipient weight before freezing the CB, this approach would make it possible to use 100%, 37.3%, 15.2%, and 7.5% of CB units for patients weighing 10, 20, 30, or 40 kg, respectively (data not shown). Discussion Although different studies have been performed regarding selection, collection, and processing of CB, 17,26-30 improvement in methods is needed to maximize resource utilization without compromising quality for clinical use, to increase efficacy, and to reduce the cost of CB grafting. The TNC count had the largest area under the ROC curve, confirming that it is the primary driver of the CD34+ cell content in CB. Combining 2 parameters to select CB did not lead to an improvement in the relationship between sensitivity and specificity; therefore, the TNC count as a single criterion seems to be sufficient for selecting CB units for cryopreservation. Most of the CB units not meeting the CD34+ cell content of or more had a TNC count below the ROC-selected value. These units would not have been processed for CD34+ cell content had this cutoff point been applied. It is worth mentioning that of all CB units with a TNC count more than the ROC-selected value, only 20% had a CD34+ cell count of less than These units, however, could potentially be used for double partially HLA-matched UCB transplantation in adults who otherwise are not eligible for allogeneic grafting owing to the lack of a suitable single- UCB unit, as previously reported. 14 Table 2 Descriptive Statistics for Cord Blood Units With a CD34+ Cell Count of or More According to TNC Cutoff Selection Criterion and the Requirement of CD34+ Cells per Kilogram of Patient Weight, Estimated for 10 to 40 kg (n = 466) * CD34+ MNC ( 10 6 ) Patient Weight (kg) TNC Cutoff ( 10 8 ) Mean ± SD Median ± (43.5) 70 (18.6) 35 (9.3) ± (44.4) 70 (19.1) 35 (9.5) ± (48.0) 67 (20.6) 35 (10.8) ± (53.2) 67 (24.1) 35 (12.5) ± (58.9) 64 (27.7) 35 (15.2) ± (60.6) 54 (28.7) 29 (15.4) ± (68.4) 51 (32.9) 27 (17.4) MNC, mononuclear cells; TNC, total nucleated cell. * All units met the required dose for patients weighing 10 kg; 89 units containing CD34+ did not meet the TNC content. For kg, data are given as number (percentage) in relation to the value in the 10-kg column. Optimal operating point chosen by receiver operating characteristic analysis. 724 Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR
5 Hematopathology / Original Article Patient s Weight (kg) CD34+ cell counting TNC count cutoff Percentage of Acceptable Cord Blood Units Figure 3 Percentage of cord blood units that would be available for transplantation as a function of patient weight using units meeting a CD34+ cell count determined by flow cytometry before cord blood cryopreservation, compared with the application of the parameter total nucleated cell (TNC) count selected by receiver operating characteristic curve analysis. Because CD34+ cell determination demands significant time and resources, we used our data for applying ROC curve analysis to validate current CB parameters as surrogates for CD34+ cell counting and ability to provide reliable, effective, and cost-effective criteria for the appropriate identification of CB units suitable for transplantation, avoiding the cost of processing units with a high probability of not having the required CD34+ cell content for cryopreservation and grafting purposes. We confirmed that the TNC count is the parameter that better correlates with the CD34+ cell content in UCB, in agreement with previous reports. 26,31,32 ROC curve analysis validated the current standard of TNC content of or more as an appropriate cutoff parameter for the selection of CB units containing an adequate number of CD34+ MNCs for cryopreservation for grafting purposes. From the Hematology Department, Internal Medicine Division, Dr. José Eleuterio González University Hospital of the School of Medicine of the Autonomous University of Nuevo León, Monterrey, México. Address reprint requests to Dr Jaime-Pérez: Servicio de Hematología, Hospital Universitario Dr. José E. González, Edificio Dr. Rodrigo Barragán, 2 piso, Avenida Madero y Gonzalitos S/N, Colonia Mitras Centro, Monterrey, Nuevo León, México, CP References 1. Weeks FM, Yee GC, Bartfield AA, et al. The true cost of bone marrow t ransplantation. Am J Med Sci. 1997;314: Wagner JE, Kernan NA, Steinbuch M, et al. Allogeneic sibling umbilical -cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995;346: Gluckman E, Rocha V, Boyer-Chammard A, et al, for the Eurocord Transpl ant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 1997;337: Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recip ients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339: Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335: McKenna DH, Brunstein CG. Umbilical cord blood: current status and fut ure directions. Vox Sang. 2011;100: Brocklebank AM, Sparrow RL. Enumeration of CD34+ cells in cord blood: a variation on a single-platform flow cytometric method based on the ISHAGE gating strategy. Cytometry. 2001;46: Holyoake TL, Alcorn MJ. CD34+ positive haemopoietic cells: biology and clinical applications. Blood Rev. 1994;8: Solves P, Carbonell-Uberos F, Mirabet V, et al. CD34+ cell content for selecting umbilical cord blood units for cryopreservation. Transfusion. 2007;47: Van Haute I, Lootens N, De Buck K, et al. Selecting cord blood units for storage by CD34+ cell counts. Transfusion. 2005;45: Wu JY, Liao C, Xu ZP, et al. Banking and transplantation of umbilical cord blood in Guangzhou, China. Cytotherapy. 2006;8: Novelo-Garza B, Limon-Flores A, Guerra-Marquez A, et al. Establishing a cord blood banking and transplantation program in Mexico: a single institution experience. Transfusion. 2008;48: Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated d onor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100: Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR 725
6 Jaime-Pérez et al / Umbilical Cord Blood Selection 14. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partial ly HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105: Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39: Hanley JA, McNeil BJ. The meaning and use of the area under a receive r operating characteristic (ROC) curve. Radiology. 1982;143: Solves P, Perales A, Mirabet V, et al. Optimizing donor selection in a cord blood bank. Eur J Haematol. 2004;72: Urciuoli P, Passeri S, Ceccarelli F, et al. Pre-birth selection of um bilical cord blood donors. Blood Transfus. 2010;8: Tamburini A, Malerba C, Picardi A, et al. Placental/ umbilical cord bl ood: experience of St. Eugenio Hospital collection center. Transplant Proc. 2005;37: Rubinstein P, Taylor PE, Scaradavou A, et al. Unrelated placental blo od for bone marrow reconstitution: organization of the placental blood program. Blood Cells. 1994;20: Sutherland DR, Anderson L, Keeney M, et al, for the International Soc iety of Hematotherapy and Graft Engineering. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother. 1996;5: Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificit y and predictive values. Acta Paediatr. 2007;96: Knottnerus JA, van Weel C, Muris JW. Evaluation of diagnostic procedu res. BMJ. 2002;324: Choi BC. Slopes of a receiver operating characteristic curve and like lihood ratios for a diagnostic test. Am J Epidemiol. 1998;148: Dwyer AJ. In pursuit of a piece of the ROC. Radiology. 1996;201: Jan RH, Wen SH, Shyr MH, et al. Impact of maternal and neonatal facto rs on CD34+ cell count, total nucleated cells, and volume of cord blood. Pediatr Transplant. 2008;12: Hutton EK, Hassan ES. Late vs early clamping of the umbilical cord in full-term neonates: systematic review and meta-analysis of controlled trials. JAMA. 2007;297: Skoric D, Balint B, Petakov M, et al. Collection strategies and cryop reservation of umbilical cord blood. Transfus Med. 2007;17: Meyer TP, Hofmann B, Zaisserer J, et al. Analysis and cryopreservatio n of hematopoietic stem and progenitor cells from umbilical cord blood. Cytotherapy. 2006;8: Koliakos G, Alamdari DH, Tsagias N, et al. A novel highyield volume- reduction method for the cryopreservation of UC blood units. Cytotherapy. 2007;9: Solves P, Perales A, Moraga R, et al. Maternal, neonatal and collecti on factors influencing the haematopoietic content of cord blood units. Acta Haematol. 2005;113: Nakagawa R, Watanabe T, Kawano Y, et al. Analysis of maternal and neonatal factors that influence the nucleated and CD34+ cell yield for cord blood banking. Transfusion. 2004;44: Am J Clin Pathol 2011;136: DOI: /AJCPFB6EXO7BJVLR
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
More informationFlow cytometric analysis of stem cells derived from umbilical cord blood CD34+/CD45+ enumeration and viability
Flow cytometric analysis of stem cells derived from umbilical cord blood CD34+/CD45+ enumeration and viability Doretha Thompson Dissertation in fulfillment of the requirements for the degree Magister Scientiae
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationNatasha Kekre, 1 Jennifer Philippe, 2 Ranjeeta Mallick, 3 Susan Smith, 2 and David Allan 1,2,4. 1. Introduction
Hindawi Publishing Corporation Stem Cells International Volume 2013, Article ID 124834, 6 pages http://dx.doi.org/10.1155/2013/124834 Research Article Modelling Improvements in Cell Yield of Banked Umbilical
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationHow To Transplant Cord Blood
MP 7.01.38 Placental/Umbilical Cord Blood as a Source of Stem Cells Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2015 Origination: 12/2001 Next Review: 12/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationCord Blood: Thawing & Infusion Practical Methods
Cord Blood: Thawing & Infusion Practical Methods Donna M Regan, MT(ASCP)SBB St. Louis Cord Blood Bank @ SSM Cardinal Glennon Children s s Medical Center Objectives Present variety of product configurations
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationAutomated Cord Blood Processing:
TM Automated Cord Blood Processing: A Follow-up to the Pilar Solves Study Comparing the AXP vs the Sepax Cord Blood Processing Systems CHRISTY KIM, PETRA CRAVENS, MINDY WILKE-DOUGLAS AND MITCHEL SIVILOTTI
More informationIn contrast to the very high transplant-related
Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationPublic Cord Blood Banking at the National Cord Blood Program (NCBP)
Public Cord Blood Banking at the National Cord Blood Program (NCBP) A. Scaradavou, MD Medical Director, National Cord Blood Program, New York Blood Center Associate Attending, Pediatric BMT Memorial Sloan-Kettering
More informationCell Recovery Sufficient for Adult Transplantation by Additional Cord Blood Collection From Placenta
Cell Recovery Sufficient for Adult Transplantation by Additional Cord Blood Collection From Placenta N. Tsagias, K. Kouzi-Koliakos, D. Hamidi-Alamdari, V. Karagiannis, E. Kostidou, and G. Koliakos ABSTRACT
More informationA simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences
Cytotherapy (2001) Vol. 3, No. 6, 429 433 A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences JM Alonso III 1, DM Regan 1, CE
More informationBioArchive Freezing Curve for Cord Blood
BioArchive Freezing Curve for Cord Blood Determination of the Specific Freezing in the BioArchive System to Provide the Highest Viability of Cord Blood MNC as Measured by -C Assays Introduction Freezing
More informationRecommendations to Transplant Centres Performing Cord Blood Transplants. Why Choosing the Right Thaw Method Could Save a Patient s Life
Recommendations to Transplant Centres Performing Cord Blood Transplants Vicki Antonenas Why Choosing the Right Thaw Method Could Save a Patient s Life Lynn O Donnell (USA) 1 The process of receiving, testing
More informationSection: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015
Medical Policy Manual Topic: Placental and Umbilical Cord Blood as a Source of Stem Cells Date of Origin: December 2009 Section: Transplant Last Reviewed Date: January 2015 Policy No: 45.16 Effective Date:
More informationANTHONY NOLAN SEARCH ALGORITHM FOR A BASIC CORD BLOOD UNIT SELECTION BY SERGIO QUEROL AND IRINA EVSEEVA FEBRUARY 2012
ANTHONY NOLAN SEARCH ALGORITHM FOR A BASIC CORD BLOOD UNIT SELECTION BY SERGIO QUEROL AND IRINA EVSEEVA FEBRUARY 2012 PAGE 1 OF 7 PRINCIPLES FOR A NEW ALGORITHM Once cord blood transplantation (CBT) is
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationTechnical report High-efficiency volume reduction of cord blood using pentastarch
(2001) 27, 457 461 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Technical report High-efficiency volume reduction of cord blood using pentastarch H Yang 1,2,
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2014 Origination: 12/2001 Next Review: 12/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationThe Impact of Maternal, Neonatal and Collections factors on the TNC count of an Umbilical Cord Blood Donation
The Impact of Maternal, Neonatal and Collections factors on the TNC count of an Umbilical Cord Blood Donation By: NHS Cord Blood Bank (Colindale Laboratory) Date: 26 th September 2014 NHS insert Cord your
More informationBeyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic
More informationSibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program
Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program MARK C. WALTERS, LYNN QUIROLO, ELIZABETH T. TRACHTENBERG, SANDIE EDWARDS, LISA HALE, JOANNA
More informationhematopoietic stem cells from cord blood: - costless but too expensive? Dr. Vincent Kindler Geneva Cord Blood Bank HUG vincent.kindler@hcuge.
hematopoietic stem cells from cord blood: - costless but too expensive? Dr. Vincent Kindler Geneva Cord Blood Bank HUG vincent.kindler@hcuge.ch Spring water: Manufactured by nature COSTLESS Cord Blood:
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 4/1/2011 Most Recent Review Date (Revised): 3/24/2015 Effective Date: 6/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationName of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells
Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells Policy #: 439 Latest Review Date: September 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits
More informationProcessing & Utilization of Cord Blood for Transplant
Processing & Utilization of Cord Blood for Transplant 2010-Jan Jan-15 Nicole L. Prokopishyn, PhD HPC Processing Laboratory Director Calgary Laboratory Services Overview Cord Blood Processing Pre-Freeze
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center April 30, 2014 Objectives Since
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationPreparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between
Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program ISCT 2012 Disclosures: none The problem:
More informationIn a number of genetic, hematologic, and oncologic
AMERICAN ACADEMY OF PEDIATRICS Cord Blood Banking for Potential Future Transplantation: Subject Review ABSTRACT. In recent years, umbilical cord blood, which contains a large number of hematopoietic stem
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationTransplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations.
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Placental and Umbilical Cord Blood as a Source of Stem Cells
More informationDr Saeed Al Amoudi. Consultant Hematologist King s college hospital Director of Regional Lab Jeddah
Dr Saeed Al Amoudi Consultant Hematologist King s college hospital Director of Regional Lab Jeddah MAGIC BULLET Cord Blood Banking What is Cord Blood? Cord blood is the blood left in the placenta and umbilical
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationReview Article A Review of Factors Influencing the Banking of Collected Umbilical Cord Blood Units
Stem Cells International Volume 2013, Article ID 463031, 7 pages http://dx.doi.org/10.1155/2013/463031 Review Article A Review of Factors Influencing the Banking of Collected Umbilical Cord Blood Units
More informationCORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE
CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE Dennis M. Todd, Ph.D. The New Jersey Cord Blood Bank a Division of Bergen Community Regional Blood Center Montvale, NJ Hematopoietic Stem Cell Transplantation
More informationA Public Cord Blood Bank for South Africa? i
No. 42/2007 A Public Cord Blood Bank for South Africa? i By Dr Robert Crookes MBChB (Wits), Dip. Internal Medicine (American Board of Internal Medicine, USA) Transfusion Medicine Consultant. South African
More informationOne-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers
The new england journal of medicine Original Article One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers John E. Wagner, Jr., M.D., Mary Eapen, M.B., B.S., Shelly Carter, D.Sc.,
More informationNavelstrengbloed tegen kanker
Navelstrengbloed tegen kanker THERAPIEDAG 2008: "Zorgtrajecten in kanker" Zaterdag 27 september 2008 Gasthuisberg, Leuven. Hélène Schoemans, MD KUL, Stem Cell Institute Leuven Cord blood Collection and
More informationCorrelation of umbilical cord blood volume with CD34+ cells concentration
IJBTI 2011 ;1 :11-1 5. Chandra et al. 11 ORIGINAL ARTICLE OPEN ACCESS Correlation of umbilical cord blood volume with CD34+ cells concentration Tulika Chandra, Sheeba Afreen, Ashutosh Kumar, Uma Singh
More informationRacial Diversity with High Nucleated Cell Counts and CD34 Counts Achieved in a National Network of Cord Blood Banks
Biology of Blood and Marrow Transplantation 10:269-275 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1004-0006$30.00/0 doi:10.1016/j.bbmt.2003.12.003 Racial Diversity with
More informationSepax. your child s cord blood is in safe hands. World leader in adult stem cell processing
Sepax your child s cord blood is in safe hands World leader in adult stem cell processing Biosafe Experience Credibility Innovation Dear Customer, Innovation in cell processing is our credo and this is
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center September 18, 2013 Objectives
More informationDouble cord blood transplantation
DCTH - 2 2013-113-121 REVIEW Double cord blood transplantation R. Angarano, I. Donnini, B. Bartolozzi, A. Bosi Ematologia, Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Italy SUMMARY
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationUmbilical Cord Blood Stem Cells Current Status & Future Potential
Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu
More informationUMBILICAL CORD BLOOD HARVESTING & STORAGE
Protocol: TRP009 Effective Date: October 14, 2013 UMBILICAL CORD BLOOD HARVESTING & STORAGE Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 BACKGROUND... 2 CLINICAL EVIDENCE...
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationCORD BLOOD BANKING. Vietnam 2011. The European Group for Blood and Marrow Transplantation
CORD BLOOD BANKING Vietnam 2011 The European Group for Blood and Marrow Transplantation 1974 The Charitable Way CORD BLOOD APPROACH Today global network of public cord blood banks - 500,000 cord
More informationStem cells from Cord Blood: Myths, reality and potential. Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute
Stem cells from Cord Blood: Myths, reality and potential Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute Learning objectives Understand the current usage of stem cells from
More informationOptimal timing for processing and cryopreservation of umbilical cord haematopoietic stem cells for clinical transplantation
Bone Marrow Transplantation, (1999) 23, 131 136 1999 Stockton Press All rights reserved 268 3369/99 $12. http://www.stockton-press.co.uk/bmt Optimal timing for processing and cryopreservation of umbilical
More informationUmbilical cord blood transplantation
Review article http://dx.doi.org/10.3345/kjp.2012.55.7.219 Korean J Pediatr 2012;55(7):219-223 eissn 1738-1061 pissn 2092-7258 Umbilical cord blood transplantation Hong Hoe Koo, MD 1, Hyo Seop Ahn, MD
More informationUmbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation
Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation Mary J. Laughlin, MD Associate Professor of Medicine and Pathology Dr. Donald and Ruth Weber Goodman Professor of Innovative
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationUMBILICAL CORD BLOOD STATISTICS
UMBILICAL CORD BLOOD STATISTICS INTRODUCTION Stem cells are the next frontier in medicine. Stem cells are thought to have great therapeutic and biotechnological potential. This will not only to replace
More informationCD34 numeration through the French external quality control: Impact in the implementation of new technical chapters at the European Pharmacopoeia
CD34 numeration through the French external quality control: Impact in the implementation of new technical chapters at the European Pharmacopoeia Panterne Béatrice Cells and Tissues Coordinator Batch release
More information14.0 Stem Cell Laboratory Services
Laboratory Services Contact Information: To inquire about assisting with surgical harvesting of bone marrow, cellular therapy (CT) product processing, cryopreservation, storage, or any other lab services,
More informationUMBILICAL CORD BLOOD COLLECTION
UMBILICAL CORD BLOOD COLLECTION by Frances Verter, PhD Founder & Director, Parent's Guide to Cord Blood Foundation info@parentsguidecordblood.org and Kim Petrella, RN Department of Obstetrics and Gynecology
More informationCord blood stem cells Where do we stand?
Mædica - a Journal of Clinical Medicine STATE TE-OF OF-THE THE-AR ART Cord blood stem cells Where do we stand? Ana Maria VLADAREANU, Associate Professor of Hematology, MD, PhD a, Doina MIHAILESCU b, MD,
More informationCord Blood Market Trends, circa 2014
GENReports: Market & Tech Analysis Cord Blood Market Trends, circa 2014 > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Topic Introduction and Scope The focus of this GEN
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationThe success of bone marrow or peripheral blood stem
CD34 + Cell Enumeration by Flow Cytometry A Comparison of Systems and Methodologies Alain Ngoma, MD; Shunnichi Saito, MT; Hitoshi Ohto, MD, PhD; Kazuhiko Ikeda, MD, PhD; Hiroyasu Yasuda, PhD; Kinuyo Kawabata,
More informationPACKING INFORMATION. Shipping to:
PACKING INFORMATION Cord Blood Bank (CBB) Instructions: Complete all information below. Then fax this sheet to the requesting Transplant Center AND include a copy with the shipped cord blood unit (CBU).
More informationCIGNA HEALTHCARE COVERAGE POSITION
CIGNA HEALTHCARE COVERAGE POSITION Subject Umbilical Cord Blood Banking Table of Contents Coverage Position... 1 General Background... 1 Coding/Billing Information... 3 References... 3 Revised Date...
More informationCancer: A Comparison of Cord Blood and Bone-marrow transplantation
UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER Juliet N. Barker* and John E. Wagner Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationUmbilical cord blood (UCB) is increasingly
ORIGINAL RESEARCH Comparison of cord blood thawing methods on cell recovery, potency, and infusion_2803 1..6 Donna M. Regan, Jonathan D. Wofford, and Donna A. Wall BACKGROUND: Umbilical cord blood (UCB)
More informationThe availability of haematopoietic stem or progenitor
Update Article Umbilical Cord Blood Transplantation: Newer Trends MB Agarwal Abstract During last ten years, over 4000 umbilical cord blood transplantations have been performed worldwide. The interest
More informationDeterminants of Engraftment after Double-Unit Cord Blood Transplantation
In: Broxmeyer HE, ed. Cord Blood: Biology, Transplantation, Banking, and Regulation Bethesda, MD: AABB Press, 2011 26 Determinants of Engraftment after Double-Unit Cord Blood Transplantation Doris M. Ponce,
More information低 剂 量 辐 射 对 脐 血 T 淋 巴 细 胞 膜 分 子 表 达 的 影 响 EFFECT OF LOW DOSE IRRADIATION ON EXPRESSION OF MEMBRANE MOLECULES OF T LYMPHOCYTES IN CORD BLOOD
CNIC-01513 PUTH-0001 低 剂 量 辐 射 对 脐 血 T 淋 巴 细 胞 膜 分 子 表 达 的 影 响 EFFECT OF LOW DOSE IRRADIATION ON EXPRESSION OF MEMBRANE MOLECULES OF T LYMPHOCYTES IN CORD BLOOD 中 国 核 情 报 中 心 China Nuclear Information
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationDirected/Related Cord Blood Collection by NHS Blood and Transplant
Directed/Related Cord Blood Collection by Jacqui Thompson Clinical Scientist Section Head of Specialist Procedures Stem Cells and Immunotherapies Department National Blood Service, NHSBT Birmingham Why
More informationHow To Bank A Cord Blood
REVIEW ARTICLE IJBC 2014; 7(1): A Review of Procedures Involved in Human Umbilical Cord Blood Banking and Transplantation Nikougoftar Zarif M 1 * 1. Blood Transfusion Research Center, High Institute for
More informationStatus of umbilical cord blood transplantation in the year 2001
428 J Clin Pathol 2001;54:428 434 Status of umbilical cord blood transplantation in the year 2001 JMHows Abstract Umbilical cord blood (UCB) transplantation is limited to small recipients because of the
More informationBiomedical Research 2012; 23 (3): 395-401 ISSN 0970-938X Scientific Publishers of India
Biomedical Research 2012; 23 (3): 395-401 ISSN 0970-938X Scientific Publishers of India Evaluation of procedures for quantification of CD34 + haematopoietic stem cells and viability studies in umbilical
More informationCORD BLOOD BANKING FAQ
CORD BLOOD BANKING FAQ Cord Blood & Stem Cells Q: What is umbilical cord blood (UCB)? A: Bone marrow, peripheral blood and UCB constitute the three primary sources of stem cells. Cord blood, which, until
More informationUmbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors?
Umbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors? Juliet N. Barker Memorial Sloan-Kettering Cancer Center, New York, NY Cryopreserved umbilical cord blood
More informationCord Blood Collection, Processing and Freezing Bag Sets for the Cryopreservation of Blood and Cellular Components
Cord Blood Collection, Processing and Freezing Bag Sets for the Cryopreservation of Blood and Cellular Components Facilitate each step in the collection, processing, freezing and transfusion process for
More informationUsing Cost Effectiveness Analysis to Determine Inventory Size for a National Umbilical Cord Blood Bank
Using Cost Effectiveness Analysis to Determine Inventory Size for a National Umbilical Cord Blood Bank Martin Maiers, Bioinformatics National Marrow Donor Program, USA NMDP Minneapolis, MN, USA NATIONAL
More informationUmbilical cord blood collection and separation for haematopoietic progenitor cell banking
Bone Marrow Transplantation, (1997) 19, 1023 1028 1997 Stockton Press All rights reserved 0268 3369/97 $12.00 Umbilical cord blood collection and separation for haematopoietic progenitor cell banking JA
More informationEUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases
! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center
More informationOverview of OneMatch, including the OneMatch Public Cord Blood Bank
Overview of OneMatch, including the OneMatch Public Cord Blood Bank Dr. Heidi Elmoazzen, Director OneMatch Public Cord Bank 2012-09-27 Outline Overview and Introduction Overview of the need for stem cells
More informationPublic Cord Blood Tissue Bank Committee on Health Care Services and Representative Peaden
HOUSE OF REPRESENTATIVES COMMITTEE ON HEALTH CARE SERVICES ANALYSIS BILL #: HB 2337 (PCB HCS 00-07) RELATING TO: SPONSOR(S): TIED BILL(S): Public Cord Blood Tissue Bank Committee on Health Care Services
More informationReview. Cord blood as an alternative source of haemopoietic stem cells. J. Hows, A. Nicol, P. Denning-Kendall, C. Donaldson, M. Nieda & B.
Annals of Oncology 7 (Suppi 2): 47-51, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Review Cord blood as an alternative source of haemopoietic stem cells J. Hows, A. Nicol, P. Denning-Kendall,
More informationProgram Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center
(last updated May 13, 2004) This is an activity offered by CBBS, a CMA accredited provider. Physicians attending this course may report up to 13.25 hours of Category 1 credits toward the California Medical
More informationThe Impact of Obstetric Parameters on Haematopoietic Stem Cells Extracted from the Umbilical Cord Blood in the Chinese Population
The Impact of Obstetric Parameters on Haematopoietic Stem Cells Extracted from the Umbilical Cord Blood in the Chinese Population Man-Sum TAM MBBS, MRCOG Department of Obstetrics and Gynaecology, Princess
More informationUmbilical Cord Blood Biology, Banking, and Therapeutic Use
Umbilical Cord Blood Biology, Banking, and Therapeutic Use a report by Jennifer R Willert, MD, 1 Thomas F Purdon, MD 2 and David T Harris, PhD 3 1. Assistant Clinical Professor of Pediatrics, Rady Children
More informationSaving Your Baby s Cord Blood
Saving Your Baby s Cord Blood An Important Pregnancy Decision 1-888-CORD BLOOD HEALTHY FUTURES ARE Born at CBR For every parent who wishes they could do more to protect their family s health, there s Cord
More information4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and
More informationHematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low
Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults
More informationEnumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood
Application Note Primary Cell Analysis Enumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood Cell Viability Introduction: Bone Marrow, Cord Blood, Stem
More informationUntying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood
Science and society Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood Joanne Kurtzberg, 1 Anne Drapkin Lyerly, 2 and Jeremy Sugarman 3 1 Pediatric
More informationTransmedcon 2014. Ahmedabad, Gujarat November 14-16, 2014
FACT Accreditation for Cord Blood Banks and Cellular Therapy Nadim Mahmud, MD, PhD Associate Professor of Medicine Division of Hematology/Oncology Director, Hospital Stem Cell Laboratory Blood & Marrow
More informationDisclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
More informationUmbilical Cord Blood for Transplantation: from Collection Quality to Its Use in Cerebral Palsy
Umbilical Cord Blood Review Umbilical Cord Blood for Transplantation: from Collection Quality to Its Use in Cerebral Palsy CF CHAN PhD Terry LEUNG BSc CRYOLIFE Cord Blood Bank, Cell Therapy Technologies
More information